- Japan
- /
- Food and Staples Retail
- /
- TSE:3088
MatsukiyoCocokara & Co. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Last week, you might have seen that MatsukiyoCocokara & Co. (TSE:3088) released its quarterly result to the market. The early response was not positive, with shares down 4.5% to JP¥3,218 in the past week. It looks like the results were a bit of a negative overall. While revenues of JP¥274b were in line with analyst predictions, statutory earnings were less than expected, missing estimates by 6.4% to hit JP¥32.30 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Taking into account the latest results, the most recent consensus for MatsukiyoCocokara from twelve analysts is for revenues of JP¥1.10t in 2026. If met, it would imply an okay 2.5% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to accumulate 3.4% to JP¥145. Before this earnings report, the analysts had been forecasting revenues of JP¥1.10t and earnings per share (EPS) of JP¥145 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
Check out our latest analysis for MatsukiyoCocokara
There were no changes to revenue or earnings estimates or the price target of JP¥3,350, suggesting that the company has met expectations in its recent result. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values MatsukiyoCocokara at JP¥3,900 per share, while the most bearish prices it at JP¥2,760. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's pretty clear that there is an expectation that MatsukiyoCocokara's revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 3.4% growth on an annualised basis. This is compared to a historical growth rate of 15% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 3.1% annually. So it's pretty clear that, while MatsukiyoCocokara's revenue growth is expected to slow, it's expected to grow roughly in line with the industry.
The Bottom Line
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for MatsukiyoCocokara going out to 2028, and you can see them free on our platform here..
We also provide an overview of the MatsukiyoCocokara Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:3088
MatsukiyoCocokara
Operates and manages chain stores, drug stores and insurance dispensing pharmacies in Japan.
Flawless balance sheet with proven track record and pays a dividend.
Similar Companies
Market Insights
Community Narratives


